NAUT

Nautilus Biotechnology, Inc. (NAUT) | Rumor.io

Nautilus Biotechnology

NAUT

Attention (50-day avg)0%

Attention rank (50-day avg)#767

Bullish sentiment (50-day avg)99%

Price to earnings ratio-2.36

Market capitalization141.1M

Earnings per share-0.45

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-59M

Social

What share of all stock conversation is about NAUT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.15	0.03% +0.02	0.01% +0.01	0% +0

Sep 29

The author has a bullish thesis on Nautilus Biotechnology (NAUT) and has entered a position in the stock, citing its potential for a rise.
The author is watching Nautilus Biotechnology (NAUT) for a potential rise, along with other stocks, and is keeping an eye on its price.
Nautilus Biotechnology (NAUT) is breaking out after a long consolidation, and the author believes there is a reason to look into this small stock.

Generated by AI

Sentiment

Of the messages about NAUT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	91.67% -8.33	99.44%	99.54% +18.99	98.82% +29.41
Bearish	8.33% +8.33	0.56%	0.46% -18.99	1.18% -29.41

Bullish· Jan 27

Nautilus Biotechnology's ($NAUT) DeepSeek-inspired memecoin has the potential to be valued much higher than its current price.
$NAUT is showing promising technical setups with increasing buy pressure, healthy volume, and RSI rebounding from oversold, indicating a potential breakout.
The asset has a strong support level at $0.003 and has the potential to reach $100M, with whales and notable investors already taking notice and participating in its growth.

Bearish· Aug 6

$NAUT has been subject to a pump and dump scheme, experiencing a 50% gain in 20 minutes only to crash back down.
The company's relationship with Amazon, which has backed the stock, has not improved its performance, and the stock has been tanking since.
The stock's price action in after-hours trading suggests a lack of volume and a bearish trend, with some investors calling it a "shit show" and a "dead" stock.

Generated by AI

Topics

Of the messages about NAUT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	79.07%	67.14%	21.58%
Earnings	0%	0%	0%	26.49%
Technical Analysis	100%	20.93%	20%	2.35%
Analysts	0%	0%	12.86%	24.96%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	24.62%

Feb 8

Nautilus Biotechnology, Inc. has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III, with the combined company expected to be listed on Nasdaq under the ticker symbol $NAUT.
The merger is valued at $900 million, with a $200 million PIPE financing and a closing expected in Q2.
Nautilus Biotechnology, a next-generation proteomics company, is building a combination of hardware and software to accurately and efficiently quantify the human proteome, and is expected to go public via the SPAC merger.

Generated by AI

Community

Of the messages about NAUT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	4.76%	89.2%	85.34%	69.31%
Newcomers	95.24%	10.8%	14.66%	30.69%

Sep 29

One newcomer is investing in $NAUT, citing a thesis from a successful investor who is a big ImmunityBio investor, with a position of 20k shares at $1.36.
Another newcomer questions the value of $NAUT, wondering what it can do that mass spectrometry cannot, suggesting that $NAUT may be overvalued.
Several newcomers are optimistic about $NAUT, citing its potential to break through resistance levels and reach targets of $1.50, $1.60, and $1.77.

Generated by AI

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J. Fox Foundation supporting our alpha-synuclein proteoform assay development, together with revenue from our first Iterative Mappi

2mo agoYahoo Finance

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the

2mo agoYahoo Finance

Also Discussed

Investors talking about NAUT also mention

#	Name	Attention
1	OLK - Olink Holding AB (publ)	——
2	Seer, Inc. Class A Common StockSEER	0%0
3	NXC - Nuveen California Select Tax-Free Income Portfolio	——
4	Via Transportation Inc. Class A Common StockVIA	0%0
5	First Trust Senior Floating Rate Income Fund IIFCT	0%0
6	Bitcoin Depot Inc.BTM	0%0
7	ARCH - Arch Resources, Inc.	——
8	MainStreet Bancshares Inc.MNSB	0%0
9	Quantum-Si Incorporated Class A Common StockQSI	0.02%+0.02
10	Vanguard Communication Services ETFVOX	0%new

Nautilus Biotechnology, Inc.

Healthcare
Biotechnology

Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and analysis tools into an integrated workflow. Its current products and systems support single-molecule protein analysis and multi-cycle proteome mapping, serving research-oriented markets in biotechnology, pharmaceuticals, and academic science. The company’s platform is intended to help scientists examine protein complexity more deeply, supporting applications in biomedical research, disease biology, and drug discovery. Headquartered in Seattle, Washington, with research and development operations in San Carlos, California, Nautilus Biotechnology operates as a development-stage company in the life sciences tools segment.

Website

Location

2701 Eastlake Avenue East

Seattle, WA, 98102

United States

Social

What share of all stock conversation is about NAUT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.15	0.03% +0.02	0.01% +0.01	0% +0

Sep 29

The author has a bullish thesis on Nautilus Biotechnology (NAUT) and has entered a position in the stock, citing its potential for a rise.
The author is watching Nautilus Biotechnology (NAUT) for a potential rise, along with other stocks, and is keeping an eye on its price.
Nautilus Biotechnology (NAUT) is breaking out after a long consolidation, and the author believes there is a reason to look into this small stock.

Generated by AI

Sentiment

Of the messages about NAUT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	91.67% -8.33	99.44%	99.54% +18.99	98.82% +29.41
Bearish	8.33% +8.33	0.56%	0.46% -18.99	1.18% -29.41

Bullish· Jan 27

Nautilus Biotechnology's ($NAUT) DeepSeek-inspired memecoin has the potential to be valued much higher than its current price.
$NAUT is showing promising technical setups with increasing buy pressure, healthy volume, and RSI rebounding from oversold, indicating a potential breakout.
The asset has a strong support level at $0.003 and has the potential to reach $100M, with whales and notable investors already taking notice and participating in its growth.

Bearish· Aug 6

$NAUT has been subject to a pump and dump scheme, experiencing a 50% gain in 20 minutes only to crash back down.
The company's relationship with Amazon, which has backed the stock, has not improved its performance, and the stock has been tanking since.
The stock's price action in after-hours trading suggests a lack of volume and a bearish trend, with some investors calling it a "shit show" and a "dead" stock.

Generated by AI

Topics

Of the messages about NAUT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	79.07%	67.14%	21.58%
Earnings	0%	0%	0%	26.49%
Technical Analysis	100%	20.93%	20%	2.35%
Analysts	0%	0%	12.86%	24.96%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	24.62%

Feb 8

Nautilus Biotechnology, Inc. has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III, with the combined company expected to be listed on Nasdaq under the ticker symbol $NAUT.
The merger is valued at $900 million, with a $200 million PIPE financing and a closing expected in Q2.
Nautilus Biotechnology, a next-generation proteomics company, is building a combination of hardware and software to accurately and efficiently quantify the human proteome, and is expected to go public via the SPAC merger.

Generated by AI

Community

Of the messages about NAUT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	4.76%	89.2%	85.34%	69.31%
Newcomers	95.24%	10.8%	14.66%	30.69%

Sep 29

One newcomer is investing in $NAUT, citing a thesis from a successful investor who is a big ImmunityBio investor, with a position of 20k shares at $1.36.
Another newcomer questions the value of $NAUT, wondering what it can do that mass spectrometry cannot, suggesting that $NAUT may be overvalued.
Several newcomers are optimistic about $NAUT, citing its potential to break through resistance levels and reach targets of $1.50, $1.60, and $1.77.

Generated by AI

Nautilus Biotechnology

Social

Sep 29

Sentiment

Bullish· Jan 27

Bearish· Aug 6

Topics

Feb 8

Community

Sep 29

News

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

Also Discussed

Nautilus Biotechnology, Inc.

Company Information

Location

News

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

Also Discussed

Social

Sep 29

Sentiment

Bullish· Jan 27

Bearish· Aug 6

Topics

Feb 8

Community

Sep 29